| River Terrace Rehabilitation And Healthcare Ctr | |
| 1675 North Main Street, Lancaster, Massachusetts 01523 | |
| (978) 365-4537 | |
| Name | River Terrace Rehabilitation And Healthcare Ctr |
|---|---|
| Location | 1675 North Main Street, Lancaster, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 82 |
| Occupancy Rate | 90.12% |
| Medicare ID (CCN) | 225210 |
| Legal Business Name | River Terrace Operator Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1578988010 |
| Organization Name | RIVER TERRACE OPERATOR LLC |
| Doing Business As | RIVER TERRACE AND REHABILITATION AND HEALTHCARE CENTER |
| Address | 1675 Main St, Lancaster, MA 01523 |
| Phone Number | 978-365-4537 |
News Archive
An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.
Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.
Research led by the Centenary Institute has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.
Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.
Research led by the Centenary Institute has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.87 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.83 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 82.14 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.58 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.35 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.03 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.03 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 91.89 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.56 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 20.7 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.94 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.6 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.95 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 95.16 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 76.42 | 82.93 |
News Archive
An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.
Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.
Research led by the Centenary Institute has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
› Verified 7 days ago
River Terrace Rehabilitation And Healthcare Ctr Location: 1675 North Main Street, Lancaster, Massachusetts 01523 Phone: (978) 365-4537 |